EXEL vs RVMD
Exelixis vs Revolution Medicines, Inc. — AI-powered side-by-side comparison
VS
RVMD
Revolution Medicines, Inc.
61
Buy
| Metric | EXEL | RVMD |
|---|
| AI Score |
67
|
61
|
| Price |
$51.30
|
$205.54
|
| P/E Ratio |
15.60×
|
-23.20×
|
| ROE |
36.2%
|
-69.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
0.0%
|
| Debt / Equity |
0.09×
|
0.25×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
70.9
|
| Beta |
0.422
|
1.403
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus RVMD.
EXEL leads by 6 points.
EXEL scores 67/100 (Buy) versus RVMD at 61/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
RVMD Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 9.4x prices in significant intangible value — Value
- ROE of only -54.1% -- cheap may mean cheap for a reason — Value
- RSI at 71 is in overbought territory — Technical